|
Volumn 90, Issue 4, 2011, Pages 493-495
|
The impact of pharmacogenomics on the management of cardiac disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
APOLIPOPROTEIN C1;
ARGININE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BUCINDOLOL;
CLMN PROTEIN;
CLOPIDOGREL;
CYTOCHROME P450 2C19;
CYTOCHROME P450 2C9;
CYTOCHROME P450 2D6;
DABIGATRAN;
FLUINDOSTATIN;
HYDRALAZINE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
KINESIN LIKE PROTEIN 6;
MULTIDRUG RESISTANCE PROTEIN 1;
NITRATE;
ORGANIC ANION TRANSPORTER 2;
PRASUGREL;
PRAVASTATIN;
PROTEIN;
SIMVASTATIN;
TICAGRELOR;
UNCLASSIFIED DRUG;
VKORC1 PROTEIN;
WARFARIN;
ACUTE CORONARY SYNDROME;
AFRICAN AMERICAN;
CARDIOVASCULAR DISEASE;
COST EFFECTIVENESS ANALYSIS;
DRUG DOSE COMPARISON;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG RESPONSE;
DRUG SAFETY;
DRUG USE;
DRUG WITHDRAWAL;
GENETIC ASSOCIATION;
GENETIC VARIABILITY;
GENOTYPE;
HEART ATRIUM FIBRILLATION;
HEART DISEASE;
HEART FAILURE;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
LOW DRUG DOSE;
MYALGIA;
MYOPATHY;
PHARMACOGENOMICS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RHABDOMYOLYSIS;
SINGLE NUCLEOTIDE POLYMORPHISM;
STROKE;
CARDIOVASCULAR DISEASES;
HEALTH BEHAVIOR;
HUMANS;
WORLD HEALTH;
|
EID: 80053006359
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.2011.187 Document Type: Review |
Times cited : (15)
|
References (6)
|